{"id":"W1978871709","doi":"10.1158/0008-5472.sabcs12-p3-06-34","title":"Abstract P3-06-34: Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC)","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Bevacizumab; Taxane; Population; Oncology; Breast cancer; Anthracycline; Cancer; Clinical endpoint; Triple-negative breast cancer; Chemotherapy; Metastatic breast cancer; Randomized controlled trial; Epirubicin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001621904,0.0006748945,0.00108045,0.0002538665,0.0003094049,0.0007245036,0.000482844,0.0007836564,0.004762142],"category_scores_gemma":[0.001222833,0.0002585341,0.0006340807,0.0002759581,0.0004040812,0.0004082289,0.0003604247,0.002010691,0.0007751926],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006982227,"about_ca_system_score_gemma":0.001083773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001015748,"about_ca_topic_score_gemma":0.001502637,"domain_scores_codex":[0.9994333,0.0003078938,0.00002723604,0.00009039827,0.00007249697,0.00006864151],"domain_scores_gemma":[0.9991793,0.0001702321,0.0001787076,0.00006755447,0.00006314636,0.000341144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8757378,0.01698956,0.01245222,0.0002954865,0.001164726,0.00007676103,0.00006072251,0.001110664,0.02541348,0.0001921204,0.007965186,0.05854123],"study_design_scores_gemma":[0.5109802,0.3821751,0.08285687,0.00005158908,0.001856289,0.0003163235,0.00005054144,0.002270997,0.01239744,0.0004915902,0.006508935,0.00004413982],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891942,0.001468603,0.0005241771,0.0005593222,0.00008435854,0.001700233,0.003349946,0.00006613332,0.003053036],"genre_scores_gemma":[0.9872376,0.0004701508,0.001418804,0.0008167484,0.0001416879,0.001481977,0.005308326,0.00002686574,0.003097746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004762142,"threshold_uncertainty_score":0.01593095,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1245295558666183,"score_gpt":0.4566840390582763,"score_spread":0.3321544831916579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}